Sotera Health Company (SHC) Balance Sheet

The improvement appears driven almost entirely by equity accumulation rather than debt reduction, since total debt has been essentially flat across the ten quarters. Retained earnings remain deeply negative at roughly -$394M, suggesting the rebuild is still early and reliant on current-period profits. Investors should monitor whether this trajectory continues, as a leverage ratio above 3.0 still limits financial flexibility.

The stability of the debt balance across ten quarters suggests management has not pursued material deleveraging, with refinancing and interest costs likely absorbing a meaningful share of operating cash flow. Debt/Assets remains high given total assets of about $3.4B, which means most of the asset base is financed by creditors. This structure may indicate that cash flow durability is being tested by fixed obligations, warranting closer review of interest coverage.

The rebound in liquidity appears to reflect both cash accumulation and working capital discipline in the most recent quarters. Cash levels, however, remain modest relative to the $2.3B debt stack, so liquidity buffers against shocks such as settlement payouts are still limited. The trend is directionally positive but does not yet provide a substantial cushion against a material legal or compliance outflow.

The heavy weighting toward PP&E reflects the capital-intensive nature of irradiation and chemical processing facilities, which supports the moat thesis but also ties returns to continued facility investment. Goodwill of roughly $1.1B, largely inherited from acquisitions, introduces impairment risk if segment performance weakens or regulatory costs rise. Investors should consider that the tangible asset base is smaller than headline totals suggest.